Sciele and Plethora present PSD502 PE data

Sciele Pharma, part of Japan's Shionogi, and the UK's Plethora Solutions presented results from a Phase III randomized, double-blind,  placebo-controlled study of PSD502 (lidocaine/prilocaine) metered-dose  aerosol for the treatment of premature ejaculation at the American  Urological Association's annual meeting.

Final analyses confirmed that PSD502 produced a highly clinically- and  statistically-significant increase from baseline in all three co-primary  study endpoints, and also in all secondary endpoints. Of patients who  received the drug, 91% achieved an intravaginal ejaculatory latency time  of greater than one minute and 75% achieved greater than two minutes,  compared with only 54% and 22% of placebo patients, respectively. The  treatment was rated positively by 86% of patients compared with 34% on  placebo.